Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.
Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion
CNBC·CNBC··1 min read
C
Continue reading on CNBC
This article was sourced from CNBC's RSS feed. Visit the original for the complete story.